Lo S S, Cheng D K, Ng T Y, Wong L C, Ngan H Y
Department of Obstetrics and Gynaecology, University of Hong Kong, Hong Kong.
Tumour Biol. 1997;18(4):241-9. doi: 10.1159/000218037.
Serum cancer antigen (CA) 125, CA15.3, CA19.9, carcinoembryonic antigen and tissue polypeptide antigen were analyzed in 100 normal subjects, 47 patients with benign gynaecological diseases and 97 patients with endometrial cancer. The incidence of individual elevated tumour markers (> 2SD) was 21.5-30.9% in cancer patients. Elevations of CA125 and CA15.3 were significantly associated with poor prognostic clinical factors. Univariate anaylses showed that elevated CA125, CA15.3 and CA19.9 were significantly associated with shorter survival. In multivariate analysis, CA15.3 was highly significant and had a larger hazard ratio. In conclusion, CA15.3 is a useful marker for the prognosis of patients with endometrial cancer.
对100名正常受试者、47例妇科良性疾病患者和97例子宫内膜癌患者的血清癌抗原（CA）125、CA15.3、CA19.9、癌胚抗原和组织多肽抗原进行了分析。癌症患者中单个肿瘤标志物升高（>2SD）的发生率为21.5 - 30.9%。CA125和CA15.3的升高与不良预后临床因素显著相关。单因素分析显示，CA125、CA15.3和CA19.9升高与较短生存期显著相关。多因素分析中，CA15.3具有高度显著性且风险比更大。总之，CA15.3是子宫内膜癌患者预后的有用标志物。
